Site US10077 — Nashville, Tennessee

Site US10077 is a clinical research site located in Nashville, Tennessee, United States 37232.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Site US10077 has participated in 1 clinical trials.

Therapeutic areas: HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2).

Sponsors: Astellas Pharma Global Development, Inc..

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site US10077?

Site US10077 has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site US10077 conducted?

Site US10077 has 1 clinical trials on record. Their work covers HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2).

Is Site US10077 accredited by Crixeo Health?

Site US10077 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site US10077?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.